A Laboratory Model for Heroin Abuse Medications - 8

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine; Fentanyl; Heroin; Methadone; Morphine; Oxycodone

Criteria

Inclusion Criterion

1. DSM IV criteria for opioid dependence

2. No major mood, psychotic, or anxiety disorder

3. Physically healthy

4. Able to perform study procedures

5. 21-45 years of age

6. Current use of i.v. heroin in amounts/frequencies

7. Not seeking treatment for opioid dependence

Exclusion Criterion

1. DSM IV criteria for dependence on drugs other

2. Participants requesting treatment

3. Participants on parole or probation

4. Pregnancy or lactation

5. Birth, miscarriage or abortion with 6 months

6. Recent history of or current significant violent behavior

7. Current major Axis I psychopathology, other than heroin dependence ( e.g., mood disorder with functional impairment or suicide risk, schizophrenia), which might interfere with ability to participate in the study

8. Hepatitis with SGOT or SGPT > 3 times normal

9. Significant suicide risk

10. Current or history of chronic pain

11. Sensitivity, allergy, or contraindication to opioids